• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing Idorsia (SWX:IDIA) Valuation After Recent Share Price Volatility

    Simply Wall St·01/06/2026 23:35:41
    Listen to the news

    Idorsia (SWX:IDIA) has drawn investor attention after recent share price swings, with the stock closing at CHF 3.70. With mixed short term returns and a low value score of 2, fundamentals are under closer scrutiny.

    See our latest analysis for Idorsia.

    The recent 1 day share price return of an 8.87% decline to CHF 3.70 extends a softer trend, with a 7 day share price return of a 13.04% decline and a 90 day share price return of a 21.28% decline, even as the 1 year total shareholder return is very large, hinting that momentum has cooled after a sharp rebound and that investors are reassessing growth prospects and risk.

    If Idorsia’s swings have you reassessing your watchlist, it could be a useful moment to compare with other pharma stocks with solid dividends that offer a different mix of income and risk.

    With a low value score of 2, a price of CHF 3.70 and a very large 1 year total return, the key question is whether Idorsia is now cheap after volatility or if the market already reflects expectations for future growth.

    Most Popular Narrative: 26% Undervalued

    At a last close of CHF 3.70 against a narrative fair value of CHF 5.00, the current price sits well below that reference point, putting the focus firmly on whether Idorsia can deliver the growth and profitability implied.

    The analysts have a consensus price target of CHF2.0 for Idorsia based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be CHF354.7 million, earnings will come to CHF72.6 million, and it would be trading on a PE ratio of 8.7x, assuming you use a discount rate of 7.2%.

    Read the complete narrative.

    Curious what earnings path and margin shift would need to sit behind that higher fair value, and why a richer future P/E is being used? The full narrative lays out the revenue build, profitability swing, and valuation multiple assumptions that have to come together for CHF 5.00 to make sense.

    Result: Fair Value of $5 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still clear swing factors here, including whether QUVIVIQ uptake and TRYVIO’s resistant hypertension launch actually track the growth path embedded in those fair value assumptions.

    Find out about the key risks to this Idorsia narrative.

    Build Your Own Idorsia Narrative

    If you are not on board with this view or simply want to test your own assumptions against the same inputs, you can review the data, adjust the drivers, and build a personalised Idorsia thesis in just a few minutes with Do it your way.

    A great starting point for your Idorsia research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    If Idorsia has sparked your interest, do not stop here. Use this moment to widen your watchlist and pressure test your thesis against other focused ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.